Evolving role of surgical treatment in limited-disease small cell lung carcinoma.
The diagnostic role of surgical procedures in small cell lung carcinoma (SCLC) is well established. The therapeutic role of surgery has changed over the years. At present, curative resection is the treatment of choice in peripheral T1-2 N0M0 SCLC, and adjuvant chemotherapy may be beneficial. Surgery is also indicated in SCLC patients diagnosed by a limited pathologic sample in whom the clinical course suggests nonsmall cell lung carcinoma (NSCLC). The resection may reveal either a mixed tumor or an alternate diagnosis and may be potentially curative. Surgery, at the time of maximal response to chemotherapy in T3N0M0 SCLC, may be curative and reveal the presence of NSCLC elements. The best survival is in patients found to be tumor-free at surgery, and the worst survival is in N2 patients.
Sridhar
K S
KS
Department of Oncology, Papanicolaou Comprehensive Cancer Center, University of Miami School of Medicine, FL 33136.
Hussein
A M
AM
Thurer
R J
RJ
D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000473:pathology / Q000601:surgery; D018288:Carcinoma, Small Cell / Q000188:drug therapy / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D003131:Combined Modality Therapy; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000473:pathology / Q000601:surgery*